keyword
MENU ▼
Read by QxMD icon Read
search

Thompson melanoma

keyword
https://www.readbyqxmd.com/read/29341162/impact-of-genomics-on-the-surgical-management-of-melanoma
#1
REVIEW
P M Ferguson, G V Long, R A Scolyer, J F Thompson
BACKGROUND: Although surgery for early-stage melanoma offers the best chance of cure, recent advances in molecular medicine have revolutionized the management of late-stage melanoma, leading to significant improvements in clinical outcomes. Research into the genomic drivers of disease and cancer immunology has not only ushered in a new era of targeted and immune-based therapies for patients with metastatic melanoma, but has also provided new tools for monitoring disease recurrence and selecting therapeutic strategies...
January 2018: British Journal of Surgery
https://www.readbyqxmd.com/read/29335541/modulation-of-uvb-induced-carcinogenesis-by-activation-of-alternative-dna-repair-pathways
#2
Yan Sha, Vladimir Vartanian, Nichole Owen, Stephanie J Mengden Koon, Marcus J Calkins, Courtney S Thompson, Zahra Mirafzali, Sara Mir, Lisa E Goldsmith, Huaping He, Chun Luo, Scott M Brown, Paul W Doetsch, Andy Kaempf, Jeong Y Lim, Amanda K McCullough, R Stephen Lloyd
The molecular basis for ultraviolet (UV) light-induced nonmelanoma and melanoma skin cancers centers on cumulative genomic instability caused by inefficient DNA repair of dipyrimidine photoproducts. Inefficient DNA repair and subsequent translesion replication past these DNA lesions generate distinct molecular signatures of tandem CC to TT and C to T transitions at dipyrimidine sites. Since previous efforts to develop experimental strategies to enhance the repair capacity of basal keratinocytes have been limited, we have engineered the N-terminally truncated form (Δ228) UV endonuclease (UVDE) from Schizosaccharomyces pombe to include a TAT cell-penetrating peptide sequence with or without a nuclear localization signal (NLS): UVDE-TAT and UVDE-NLS-TAT...
January 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29330716/long-term-survival-of-patients-with-thin-t1-cutaneous-melanomas-a-breslow-thickness-cut-point-of-0-8%C3%A2-mm-separates-higher-risk-and-lower-risk-tumors
#3
Serigne N Lo, Richard A Scolyer, John F Thompson
BACKGROUND: Counterintuitively, more deaths from melanoma occur among patients with thin (T1) primary melanomas (≤ 1 mm) than among those with thick primary melanoma because the great majority present with T1 tumors. Therefore, it is important to stratify their risk as accurately as possible to guide their management and follow-up. This study sought to explore the relationship between tumor thickness and prognosis for patients with thin primary melanomas. METHODS: A retrospective, single-institution study investigated 6263 patients with cutaneous melanoma (including 2117 T1 cases) who had a minimum follow-up period of 10 years...
January 12, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29299710/follow-up-recommendations-after-diagnosis-of-primary-cutaneous-melanoma-a-population-based-study-in-new-south-wales-australia
#4
Rebecca L Read, Christine M Madronio, Anne E Cust, Chris Goumas, Caroline G Watts, Scott Menzies, Austin M Curtin, Graham Mann, John F Thompson, Rachael L Morton
BACKGROUND: Follow-up practices after diagnosis and treatment of primary cutaneous melanoma vary considerably. We aimed to determine factors associated with recommendations for follow-up setting, frequency, skin surveillance, and concordance with clinical guidelines. METHODS: The population-based Melanoma Patterns of Care study documented clinicians' recommendations for follow-up for 2148 patients diagnosed with primary cutaneous melanoma over a 12-month period (2006/2007) in New South Wales, Australia...
January 3, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29278663/do-australian-adolescent-and-young-adults-experiences-of-cancer-care-influence-their-quality-of-life
#5
Gemma Skaczkowski, Victoria White, Kate Thompson, Helen Bibby, Michael Coory, Ross Pinkerton, Lisa M Orme, Rachel Conyers, Marianne B Phillips, Michael Osborn, Rosemary Harrup, Antoinette Anazodo
OBJECTIVE: To examine the relationship between the cancer care experiences of adolescents and young adults (AYAs) and their quality of life. METHODS: 209 AYAs completed a cross-sectional, self-report survey distributed through the population-based cancer registries in two Australian states (New South Wales and Victoria). Eligible AYAs were diagnosed at 15-24 years old with any cancer (excluding early stage melanoma) and were 3-24 months post-diagnosis. Questions examined whether particular care experiences occurred for the patient at different points in the cancer care pathway, including diagnosis, treatment, inpatient care and at the end of treatment...
December 26, 2017: Psycho-oncology
https://www.readbyqxmd.com/read/29261570/quality-of-life-patient-reported-outcomes-for-locally-advanced-cutaneous-melanoma
#6
Evan S Weitman, Matthew Perez, John F Thompson, Robert H I Andtbacka, Jo Dalton, Mona L Martin, Talia Miller, Chad Gwaltney, David Sarson, Eric Wachter, Jonathan S Zager
Locally advanced cutaneous melanoma has marked quality-of-life implications; however, the patient experience of symptom management and subsequent impact on quality of life has not been well described. This study aims to address the impact on patients of advanced cutaneous melanoma through qualitative interviews. Adults with stage IIIB, IIIC, or IV (M1a) cutaneous melanoma were recruited from two cancer centers in the USA and one in Australia. Telephone interviews were conducted to assess how locoregionally advanced cutaneous melanoma impacted everyday life...
December 19, 2017: Melanoma Research
https://www.readbyqxmd.com/read/29240580/prognostic-significance-of-periadnexal-extension-in-cutaneous-melanoma-and-its-implications-for-pathologic-reporting-and-staging
#7
Tristan J Dodds, Serigne Lo, Louise Jackett, Omgo Nieweg, John F Thompson, Richard A Scolyer
Tumor thickness is the strongest predictor of outcome for clinically localized melanoma. Therefore, accurate assessment is critical for appropriate staging, reliable estimation of prognosis, and management. When melanoma extends alongside skin adnexal structures more deeply than the main tumor mass (periadnexal extension), it is currently unknown whether the prognosis is more accurately reflected by the deepest point of periadnexal tumor extension or the main tumor mass. This study sought to address this question...
December 7, 2017: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29227041/a-14-protein-signature-for-rapid-identification-of-poor-prognosis-stage-iii-metastatic-melanoma
#8
Erin K Sykes, Cassandra E McDonald, Shila Ghazanfar, Swetlana Mactier, John F Thompson, Richard A Scolyer, Jean Y Yang, Graham J Mann, Richard I Christopherson
PURPOSE: To validate differences in protein levels between good and poor prognosis AJCC stage III melanoma patients and compile a protein panel to stratify patient risk. EXPERIMENTAL DESIGN: Protein extracts from melanoma metastases within lymph nodes in patients with Stage III disease with good (n = 16, > 4 years survival) and poor survival (n = 14, < 2 years survival) were analysed by selected reaction monitoring (SRM). Diagonal Linear Discriminant Analysis was performed to generate a protein biomarker panel...
December 11, 2017: Proteomics. Clinical Applications
https://www.readbyqxmd.com/read/29187357/iap-antagonists-enhance-cytokine-production-from-mouse-and-human-inkt-cells
#9
Eleanor Clancy-Thompson, Lestat Ali, Patrick T Bruck, Mark A Exley, Richard S Blumberg, Glenn Dranoff, Michael Dougan, Stephanie K Dougan
Inhibitor of apoptosis protein (IAP) antagonists are in clinical trials for a variety of cancers, and mouse models show synergism between IAP antagonists and anti-PD-1 immunotherapy. Although IAP antagonists affect the intrinsic signaling of tumor cells, their most pronounced effects are on immune cells and the generation of antitumor immunity. Here we examined the effects of IAP antagonism on T-cell development using mouse fetal thymic organ culture and observed a selective loss of iNKT cells, an effector cell type of potential importance for cancer immunotherapy...
November 29, 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/29102486/merkel-cell-carcinoma-current-united-states-incidence-and-projected-increases-based-on-changing-demographics
#10
Kelly G Paulson, Song Youn Park, Natalie A Vandeven, Kristina Lachance, Hannah Thomas, Aude G Chapuis, Kelly L Harms, John A Thompson, Shailender Bhatia, Andreas Stang, Paul Nghiem
BACKGROUND: Merkel cell carcinoma (MCC) incidence rates are rising and strongly age-associated, relevant for an aging population. OBJECTIVE: Determine MCC incidence in the United States and project incident cases through the year 2025. METHODS: Registry data were obtained from the SEER-18 database, containing 6,600 MCC cases. Age and sex-adjusted projections were generated utilizing US census data. RESULTS: Between 2000-2013, there was a 95% increase in the number of reported MCC cases, compared to 57% for melanoma and 15% for all 'solid' cancers...
November 1, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/29028110/melanoma-staging-evidence-based-changes-in-the-american-joint-committee-on-cancer-eighth-edition-cancer-staging-manual
#11
Jeffrey E Gershenwald, Richard A Scolyer, Kenneth R Hess, Vernon K Sondak, Georgina V Long, Merrick I Ross, Alexander J Lazar, Mark B Faries, John M Kirkwood, Grant A McArthur, Lauren E Haydu, Alexander M M Eggermont, Keith T Flaherty, Charles M Balch, John F Thompson
Answer questions and earn CME/CNE To update the melanoma staging system of the American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, and III melanoma diagnosed since 1998. Based on analyses of this new database, the existing seventh edition AJCC stage IV database, and contemporary clinical trial data, the AJCC Melanoma Expert Panel introduced several important changes to the Tumor, Nodes, Metastasis (TNM) classification and stage grouping criteria...
November 2017: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/29020893/clinical-practice-guidelines-for-the-diagnosis-and-management-of-melanoma-melanomas-that-lack-classical-clinical-features
#12
Victoria J Mar, Alex J Chamberlain, John W Kelly, William K Murray, John F Thompson
A Cancer Council Australia multidisciplinary working group is currently revising and updating the 2008 evidence-based clinical practice guidelines for the management of cutaneous melanoma. While there have been many recent improvements in treatment options for metastatic melanoma, early diagnosis remains critical to reducing mortality from the disease. Improved awareness of the atypical presentations of this common malignancy is required to achieve this. A chapter of the new guidelines was therefore developed to aid recognition of atypical melanomas...
October 16, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/29019177/long-term-survival-after-complete-surgical-resection-and-adjuvant-immunotherapy-for-distant-melanoma-metastases
#13
Mark B Faries, Nicola Mozzillo, Mohammed Kashani-Sabet, John F Thompson, Mark C Kelley, Ronald C DeConti, Jeffrey E Lee, James F Huth, Jeffrey Wagner, Angus Dalgleish, Daniel Pertschuk, Christopher Nardo, Stacey Stern, Robert Elashoff, Guy Gammon, Donald L Morton
BACKGROUND: This phase III study was undertaken to evaluate the efficacy of an allogeneic whole-cell vaccine (Canvaxin™) plus bacillus Calmette-Guerin (BCG) after complete resection of stage IV melanoma. METHODS: After complete resection of ≤5 distant metastases, patients were randomly assigned to BCG+Canvaxin (BCG/Cv) or BCG+placebo (BCG/Pl). The primary endpoint was overall survival (OS); secondary endpoints were disease-free survival (DFS), and immune response measured by skin test (ClinicalTrials...
October 10, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28964611/incidental-detection-of-colorectal-lesions-by-fdg-pet-ct-scans-in-melanoma-patients
#14
Christopher J Young, Assad Zahid, Ian Choy, John F Thompson, Robyn P M Saw
BACKGROUND: Increased use of PET/CT scans in oncology patients has raised detection of Colorectal incidentalomas (CIs). The frequency and diagnostic outcomes of identifying these lesions in melanoma patients have not previously been studied. This studies primary objective was to determine the prevalence of CIs found on PET/CT scans in melanoma patients. The secondary objectives were to correlate the PET/CT findings with the pathology found at colonoscopy, and identify which patients were referred for colonoscopy...
September 19, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28947567/4-1bb-agonist-focuses-cd8-tumor-infiltrating-t-cell-growth-into-a-distinct-repertoire-capable-of-tumor-recognition-in-pancreatic-cancer
#15
Donastas Sakellariou-Thompson, Marie-Andrée Forget, Caitlin Creasy, Vincent Bernard, Li Zhao, Young Uk Kim, Mark W Hurd, Naohiro Uraoka, Edwin Roger Parra, Ya'an Kang, Christopher A Bristow, Jaime Rodriguez-Canales, Jason B Fleming, Gauri Varadhachary, Milind Javle, Michael J Overman, Hector A Alvarez, Timothy P Heffernan, Jianhua Zhang, Patrick Hwu, Anirban Maitra, Cara Haymaker, Chantale Bernatchez
Purpose: Survival for pancreatic ductal adenocarcinoma (PDAC) patients is extremely poor and improved therapies are urgently needed. Tumor-infiltrating lymphocyte (TIL) adoptive cell therapy (ACT) has shown great promise in other tumor types, such as metastatic melanoma where overall response rates of 50% have been seen. Given this success and the evidence showing that T-cell presence positively correlates with overall survival in PDAC, we sought to enrich for CD8+ TILs capable of autologous tumor recognition...
December 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28875280/metastases-to-the-parathyroid-glands-a-comprehensive-literature-review-of-127-reported-cases
#16
REVIEW
Justin L Bauer, Sherwin Toluie, Lester D R Thompson
Metastases to the head and neck organs are uncommon, potentially representing the initial presentation of an occult malignancy. Single case reports and small series report metastases to the parathyroid gland, but there is no large review of the literature on secondary tumors involving the parathyroid glands. A review of the English literature between 1950 and 2017 was performed of all metastases or secondary involvement of the parathyroid glands. One hundred and twenty-seven cases of metastatic tumors were reported, although potentially significantly unrepresented in autopsy series (parathyroid glands are not routinely examined) and due to reporting bias...
September 5, 2017: Head and Neck Pathology
https://www.readbyqxmd.com/read/28854100/melanoma-sentinel-node-metastasis
#17
LETTER
Mark B Faries, Alistair J Cochran, John F Thompson
No abstract text is available yet for this article.
August 31, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28799064/safety-and-efficacy-of-isolated-limb-infusion-chemotherapy-for-advanced-locoregional-melanoma-in-elderly-patients-an-australian-multicenter-study
#18
Hidde M Kroon, Brendon J Coventry, Mitchell H Giles, Michael A Henderson, David Speakman, Mark Wall, Andrew Barbour, Jonathan Serpell, Paul Paddle, Bernard M Smithers, John F Thompson
BACKGROUND: Isolated limb infusion (ILI) offers a minimally invasive treatment option for locally advanced extremity melanoma. OBJECTIVE: The aim of the current study was to evaluate the safety and efficacy of ILI in elderly patients in an Australian multicenter setting. METHODS: The results of 316 first ILI procedures, performed between 1992 and 2008 in five Australian institutions, were identified and analyzed, with the main focus on elderly patients (≥75 years of age)...
October 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28777143/assessing-tumor-infiltrating-lymphocytes-in-solid-tumors-a-practical-review-for-pathologists-and-proposal-for-a-standardized-method-from-the-international-immuno-oncology-biomarkers-working-group-part-2-tils-in-melanoma-gastrointestinal-tract-carcinomas-non
#19
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen van de Vijver, M V Estrada, Paula I Gonzalez-Ericsson, Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G G M Van den Eynden, Yves Allory, Matthias Preusser, Johannes Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nuciforo, Laura Comerma, E A Thompson, Sunil Lakhani, Seong-Rim Kim, Stuart Schnitt, Cecile Colpaert, Christos Sotiriou, Stefan J Scherer, Michail Ignatiadis, Sunil Badve, Robert H Pierce, Giuseppe Viale, Nicolas Sirtaine, Frederique Penault-Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B Johnson, Justin Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternes, Nicole Burchardi, Stephen J Luen, Peter Savas, Frederick Klauschen, Peter H Watson, Brad H Nelson, Carmen Criscitiello, Sandra O'Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice André, Magali Lacroix-Triki, Mark van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph Sparano, David Rimm, Torsten Nielsen, Zuzana Kos, Stephen Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H Allison, Nadine Tung, Sylvia Adams, Karen Willard-Gallo, Hugo M Horlings, Leena Gandhi, Andre Moreira, Fred Hirsch, Maria V Dieci, Maria Urbanowicz, Iva Brcic, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer Giltnane, Marlon C Rebelatto, Keith E Steele, Jiping Zha, Kenneth Emancipator, Jonathan W Juco, Carsten Denkert, Jorge Reis-Filho, Sherene Loi, Stephen B Fox
Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma...
November 2017: Advances in Anatomic Pathology
https://www.readbyqxmd.com/read/28776578/negative-immune-checkpoint-regulation-by-vista-a-mechanism-of-acquired-resistance-to-anti-pd-1-therapy-in-metastatic-melanoma-patients
#20
Hojabr Kakavand, Louise A Jackett, Alexander M Menzies, Tuba N Gide, Matteo S Carlino, Robyn P M Saw, John F Thompson, James S Wilmott, Georgina V Long, Richard A Scolyer
Understanding the mechanisms of acquired resistance to anti-PD-1 will allow development of better treatment strategies for cancer patients. This study evaluated potential mechanisms of acquired resistance to anti-PD-1 in longitudinally collected metastatic melanoma patient biopsies. Thirty-four metastatic melanoma biopsies were collected from 16 patients who had initially responded to either anti-PD-1 (n=13) alone or combination of anti-PD-1 and ipilimumab (n=3) and then progressed. Biopsies were taken prior to treatment (PRE, n=12) and following progression of disease (PROG, n=22)...
August 4, 2017: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
keyword
keyword
58967
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"